Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Coeptis Therapeutics Holdings ( (COEP) ) has provided an announcement.
At an Annual and Special Meeting of Stockholders held on January 30, 2026, Coeptis Therapeutics Holdings’ shareholders approved the issuance of new common stock to complete a merger with Z Squared, resulting in a change of control of the company. Investors also backed a spin-out of Coeptis’ biopharmaceutical operations other than those run through GEAR Therapeutics, a change of the corporate name to Z Squared Inc., adoption of a new equity incentive plan for the combined company, and the election of a new board slate. Shareholders further approved the repricing or replacement of certain existing stock options, ratified Astra Audit & Advisory, LLP as the independent auditor for the 2025 fiscal year, and supported on an advisory basis the compensation of named executive officers, collectively clearing a broad restructuring and governance package that will reshape the company’s capital structure, leadership, and strategic direction.
More about Coeptis Therapeutics Holdings
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company whose operations include activities conducted through its subsidiary GEAR Therapeutics, Inc., with a focus on therapeutic development. The company is transitioning its corporate identity and control structure through a merger with Z Squared and related corporate actions, signaling a strategic shift in its operational and market focus.
Average Trading Volume: 75,582
Technical Sentiment Signal: Buy
Current Market Cap: $81.51M
See more data about COEP stock on TipRanks’ Stock Analysis page.